Ikena Oncology, Inc. (IKNA) News
Filter IKNA News Items
IKNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IKNA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IKNA News From Around the Web
Below are the latest news stories about IKENA ONCOLOGY INC that investors may wish to consider to help them evaluate IKNA as an investment opportunity.
US Penny Stocks To Watch In January 2025As the new year begins, major U.S. stock indices have extended their recent slump, with the Dow Jones Industrial Average and S&P 500 both experiencing declines. Despite these broader market challenges, penny stocks—often representing smaller or newer companies—remain an area of interest for investors seeking growth opportunities. While the term "penny stock" may seem outdated, these investments can still offer significant potential when backed by strong financials. |
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the UpgradeIkena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Ikena Oncology and Inmagene Announce Merger and FundraisingIkena Oncology ( (IKNA) ) has provided an announcement. Ikena Oncology and Inmagene Biopharmaceuticals have announced a definitive merger agreement, under which the combined company will focus on developing IMG-007, a monoclonal antibody aimed at treating atopic dermatitis and other inflammatory conditions. The transaction involves a private placement raising approximately $175 million, including $75 million from new and existing investors, and is expected to close in mid-2025. Following the mer |
Sector Update: Health Care Stocks Advance Late AfternoonHealth care stocks were higher late Monday afternoon, with the NYSE Health Care Index rising 0.9% an |
Ikena Oncology, Inmagene Sign Merger Deal; Shares RiseIkena Oncology (IKNA) and clinical-stage biotechnology company Inmagene Biopharmaceuticals said Mond |
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementInmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track Capital, Foresite Capital, |
3 US Penny Stocks With Market Caps Over $40M To ConsiderAs the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms. |
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)Ikena Oncology ( NASDAQ:IKNA ) Third Quarter 2024 Results Key Financial Results Net loss: US$10.2m (loss narrowed by... |
Ikena Oncology Reports Third Quarter 2024 Financial ResultsStrong financial position with $138 million in cash and investments at close of third quarterBOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its ongoing activities. Pipeline and Corporate Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared |
Ikena Oncology Reports Second Quarter 2024 Financial ResultsStrong financial position with $145 million in cash and investments at close of second quarterBOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety eval |